Company Monitoring Page for Otsuka

latest headlines for company on cafepharma

Proteus files for bankruptcy: Where did it falter?
MedCity News
Wed, 06/17/20 - 10:01 am
Tags:
Proteus Digital Health, Otsuka, smart pills, bankruptcy
With Bristol and Otsuka on Board, LSP Raises $620M EU Life Sciences Fund
Xconomy
Wed, 03/11/20 - 07:26 pm
Tags:
LSP, life sciences, Bristol-Myers Squibb, Otsuka, Europe
A forerunner in ‘smart pills’ adopts a new tack as key pharma partnership unravels
Stat
Tue, 01/14/20 - 10:03 am
Tags:
smart pills, Proteus Digital Health, Otsuka
Otsuka's Avanir agrees to pay $108M over Neudexta kickbacks probe
Fierce Pharma
Thu, 09/26/19 - 07:44 pm
Tags:
Avanir Pharmaceuticals, Otsuka, kickbacks, Neudexta, dementia
"Smart Pill" Schizophrenia Drug Unlikely To Move Payers
Forbes
Mon, 07/22/19 - 10:03 am
Tags:
Otsuka, Abilify MyCite, smart pills, schizophrenia, payers
Astex Pharma and Otsuka’s Cancer Trial Meets Primary Endpoints
BioSpace
Fri, 06/7/19 - 10:07 pm
Tags:
Astex, Otsuka, clinical trials, ASTX727, myelodysplastic syndrome, CMML
Verily lures major pharmas with promise of speedier clinical research
BioPharma Dive
Tue, 05/21/19 - 11:07 pm
Tags:
Verily, Alphabet, clinical trials, Pfizer, Novartis, Sanofi, Otsuka
Wockhardt receives US FDA approval for cancer drug
Pharmaceutical Business Review
Fri, 04/12/19 - 10:09 am
Tags:
Wockhardt, decitabine, FDA, generics, Otsuka, Dacogen, myelodysplastic syndromes
3 Leading Alzheimer's Disease Drugs in Development After Biogen's Aducanumab Flop
Motley Fool
Sat, 03/30/19 - 12:44 pm
Tags:
Alzheimer's disease, Biogen, aducanumab, Otsuka, Axsome Therapeutics, Amgen, Novartis, Avanir, AVP-786, AXS-05, AMG520
Pfizer CNS spinout Cerevel brings on new CMO to launch phase 3 work in Parkinson’s disease
Fierce Biotech
Wed, 02/20/19 - 06:09 pm
Tags:
Cerevel Therapeutics, Pfizer, Otsuka, CMOs, Parkinson's Disease, epilepsy
Antipsychotic from Lundbeck, Otsuka flops again in PhIII trials — this time in bipolar patients
Endpoints
Thu, 02/14/19 - 05:45 pm
Tags:
Lundbeck, Otsuka, brexpiprazole, anti-psychotic, schizophrenia, bipolar disorder
Otsuka, Click to develop digital therapeutics for MDD
Pharmaceutical Business Review
Fri, 01/4/19 - 09:09 am
Tags:
Otsuka, Click Therapeutics, digital therapeutics, major depressive disorder
Lundbeck and Otuska’s brexpiprazole hits the mark in PTSD trial
Fierce Biotech
Fri, 11/30/18 - 10:27 am
Tags:
Lundbeck, Otsuka, brexpiprazole-sertraline, PTSD, clinical trials
Otsuka's dose-tracking digital pill charts its first course to market with Magellan
Fierce Pharma
Wed, 09/5/18 - 07:02 pm
Tags:
Otsuka, Abilify MyCite, smart pills, digital pills, bipolar disorder, schizophrenia
The Line Between Drugs and Devices Continues to Blur
Medical Devices and Diagnostics Industry
Fri, 08/31/18 - 10:54 am
Tags:
Otsuka, Magellan Health, drug-device combos, devices, FDA, drug ingestion tracking
The 10 most innovative medical devices of 2018
Mass Device
Sun, 08/5/18 - 07:21 pm
Tags:
devices, Abbott Labs, Boston Scientific, BrainScope, Foundation Medicine, Integra LifeSciences, Koning Corporation, Medtronic, Otsuka
Did a blockbuster drug make hundreds gamble compulsively? A legal fight may decide what science can’t confirm
Stat
Thu, 08/2/18 - 10:01 am
Tags:
Abilify, compulsive behavior, Bristol-Myers Squibb, Otsuka
Otsuka’s $886M-plus drug just flopped in its first crucial PhIII trial for frontline AML
Endpoints
Tue, 07/31/18 - 10:14 am
Tags:
Otsuka, SGI-110, clinical trials, AML
Otsuka Ramps Up Its Antibody Game with $430M Visterra Acquisition
Xconomy
Wed, 07/11/18 - 03:12 pm
Tags:
Otsuka, Visterra, M&A
Otsuka Finds Paradise in Renal Denervation Market
Medical Devices and Diagnostics Industry
Tue, 07/10/18 - 11:01 pm
Tags:
Otsuka, ReCor Medical, renal denervation, devices, M&A

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.